# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce leukocyte migration
- describe integrin adhesion receptors
- discuss β2 integrins and ICAMs
- motivate inhibition of LFA-1/ICAM-1 binding
- summarize therapeutic potential

## SUMMARY OF THE INVENTION

- describe leukocyte-selective delivery agent
- outline method for leukocyte-selective delivery

## DETAILED DESCRIPTION OF THE INVENTION

- introduce cell type specific delivery of an agent
- describe leukocyte-selective delivery agent
- outline components of delivery agent
- describe use of delivery agent in methods
- discuss advantages of targeted delivery

### Targeting Agent

- define targeting agent
- describe examples of targeting agents
- discuss use of antibodies as targeting agents
- describe functional fragments of antibodies
- outline use of multiple targeting agents
- discuss targeting all leukocytes
- describe activation-insensitive targeting moieties
- outline targeting active or inactive leukocytes
- discuss conformational changes in integrins
- describe active conformation of integrin LFA-1
- outline targeting moieties for activated leukocytes
- discuss epitopes unique to activated integrins
- describe targeting moieties derived from ligands
- outline non-ligand mimetic targeting moieties

### Carriers for Therapeutic Agents

- introduce carrier particles
- describe liposomes as carrier particles
- modify liposome surface with targeting moiety
- describe cryoprotectants for liposomes
- detail hyaluronic acid as cryoprotectant
- describe crosslinking reagents for cryoprotectants
- modify liposomes with long-circulating agents
- describe hydrophilic polymers as long-circulating agents
- covalently attach targeting moiety to cryoprotectant
- describe unilamellar and multilamellar liposomes
- encapsulate therapeutic agent in liposome
- describe nucleic acid therapeutic agents
- condense nucleic acid with cationic polymer
- describe multi-layered liposomes
- lyophilize and rehydrate liposomes
- describe other cryoprotectants
- deliver two agents with liposome
- describe protein and nucleic acid binding domains as carrier moieties

### Therapeutic Agents

- define therapeutic agents
- describe nucleic acid therapeutic agents
- describe small molecule therapeutic agents
- describe polypeptide therapeutic agents
- describe antibody therapeutic agents
- describe functional fragments of therapeutic agents
- describe modification of therapeutic agents
- describe delivery of multiple therapeutic agents
- describe targeting proinflammatory mediators
- describe targeting tissue injury
- describe targeting cell activation and proliferation
- describe targeting cell movement/migration/invasion
- describe targeting oncogenes
- describe targeting viral diseases
- describe association of therapeutic agents with carrier particles

### Methods

- describe delivery of therapeutic agents to target cells
- describe in vivo, in vitro, and ex vivo delivery
- describe contacting targeting moiety with target cells
- describe routes of delivery
- describe subjects for therapy
- describe screening targets of pharmaceutical intervention

## Targeted Delivery of siRNA to Activated Leukocytes via Antibody Selective to High-Affinity Form of Integrin LFA-1

- develop soluble designer LFA-1 I domains
- select phage library with locked high-affinity I domain
- identify clone AL-57 that binds to open I domain
- convert Fab to intact IgG
- show AL-57 binds to LFA-1 on cell surface upon activation
- prepare immuno-nanoparticles with HA and antibodies
- characterize nanoparticles by size and surface charge
- encapsulate siRNAs with protamine or PEI
- quantify siRNA entrapment efficiency
- silence CD4 in lymphocytes with AL-57-NP
- study silencing in lymphocytes activated by physiologic inside-out signaling
- demonstrate siRNA delivery by AL-57-NP selectively to activated lymphocytes
- produce AL-57-protamine fusion protein
- show binding of AL-57-PF to cell surface LFA-1 upon activation
- study stoichiometry of siRNA binding to AL-57-PF
- silence CD4 and Ku70 in lymphocytes with AL-57-PF
- demonstrate selective silencing by AL-57-PF in activated lymphocytes
- inhibit proliferation of lymphocytes with cyclin-D1-siRNA delivered by AL-57-PF
- visualize siRNA delivery by AL-57-PF to activated lymphocytes using confocal microscopy

## Example 2.1

### Gene Silencing by AL-57-NP In Vitro

- introduce rationale for gene silencing
- describe experimental design for heterogeneous populations
- outline methods for cell isolation and activation
- detail co-culture experiment with CBRLFA-1/2
- describe cross-linking of TCR Vβ3
- outline delivery to lymphocytes, monocytes, and neutrophils
- anticipate results and potential pitfalls
- introduce IFN-response rationale
- describe quantitative RT-PCR methods
- anticipate IFN-response results and alternative approaches
- introduce impact on integrin function and signaling rationale
- describe adhesion assay methods
- outline costimulatory activity experiments
- anticipate impact on integrin function and signaling results
- discuss potential pitfalls and alternative approaches
- consider alternative delivery means

### Example 2.2

- hypothesize biphasic activation of engrafted T-cells
- study LFA-1 activation using mAbs
- analyze activation status of LFA-1
- examine binding of AL-57-NP and AL-57-PF ex vivo
- anticipate results and potential pitfalls
- consider alternative approaches
- study biodistribution and pharmacokinetics of AL-57-NP
- investigate biodistribution of protamine fusion proteins
- anticipate results and potential pitfalls
- consider alternative approaches
- study siRNA delivery and gene-silencing by AL-57-NP
- examine in vivo binding of Cy3-labeled immuno-nanoparticles
- study delivery of Cy3-siRNAs
- investigate gene-silencing by Ku70-siRNA
- anticipate results and potential pitfalls

## Discussion

### Integrin LFA-1 as Drug Delivery Target

- motivate LFA-1 as drug delivery target
- summarize LFA-1 expression in leukocytes
- describe LFA-1 internalization and recycling
- explain LFA-1 conformational changes
- discuss advantages of targeting active LFA-1

### Targeted Delivery of Liposomes for Anti-Inflammatory Therapies

- introduce liposomes as drug carrier system
- discuss targeted delivery of liposomes using antibodies and ligands

### Example 3

- express LFA-1 IgG antibodies
- convert to scFvs
- fuse with protamine peptide
- express and purify AL-57-PF and TS1/22-PF
- verify binding specificity by flow cytometry
- test siRNA delivery to PBMC
- demonstrate selective gene silencing by AL-57-PF
- silence Ku70 gene expression
- silence CD4 gene expression
- silence CCR5 gene expression
- test siRNA delivery to heterogeneous cell populations
- demonstrate selective gene silencing in activated lymphocytes
- test siRNA delivery to lymphocytes activated by TCR or chemokine stimulation
- silence cyclin D1 gene expression
- suppress proliferation of activated lymphocytes
- test in vivo siRNA delivery in SCID mice
- demonstrate specific in vivo siRNA delivery to K562 cells
- verify lack of lymphocyte activation by fusion proteins
- verify lack of IFN responses to fusion proteins
- discuss implications for targeted siRNA delivery
- describe siRNA delivery and gene silencing
- detail T lymphocyte activation through CXCR4 and TCR
- outline mixed-population transduction experiment
- describe in vivo delivery
- construct and express scFv and scFv-protamine fusion proteins
- isolate and prepare PBMC and memory T lymphocytes
- prepare siRNAs
- transfect siRNAs
- perform quantitative RT-PCR
- assay lymphocyte proliferation
- perform flow cytometry
- acquire and process images
- perform immunohistochemistry

